CervoMed CEO and 10% owner increases holdings with open-market buys

Q: How many CervoMed (CRVO) shares were bought on 11/13/2025 and at what price?

On 11/13/2025 , the reporting person bought 4,447 shares of CervoMed common stock at $7.51 per share in open-market transactions.

Q: What additional CervoMed (CRVO) shares were acquired on 11/14/2025?

On 11/14/2025 , the reporting person acquired 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA and 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA .

Q: How many CervoMed (CRVO) shares does the insider hold jointly after these trades?

The filing states that 1,471,578 shares are held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire , who is also a member of CervoMed’s Board of Directors.

Q: What price ranges applied to the weighted average CervoMed (CRVO) purchase prices?

The $7.55 weighted average price reflects purchases between $7.41 and $7.57 . The $7.57 weighted average price reflects purchases between $7.44 and $7.58 , all in open-market transactions.

Q: How is indirect ownership of CervoMed (CRVO) shares reported in this Form 4?

Indirect ownership is reported through the John J. Alam Roth IRA holding 1,693 shares and the Sylvie Gregoire Roth IRA holding 1,707 shares , in addition to jointly held shares.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

CervoMed Inc. (CRVO) reported insider buying by its CEO, President, director and 10% owner. On 11/13/2025, the reporting person bought 4,447 shares of common stock in open-market transactions at $7.51 per share. On 11/14/2025, additional open-market purchases included 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA and 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA. Following these transactions, 1,471,578 shares were held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, with separate Roth IRA holdings noted.

Insider Trade Summary

Net Buyer: 7,847 shares ($59,101)

Net Buy 3 txns

Insider ALAM JOHN J

Role CEO & President

Bought 7,847 shs ($59K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,693	$7.55	$13K
Purchase	Common Stock	1,707	$7.57	$13K
Purchase	Common Stock	4,447	$7.51	$33K

Holdings After Transaction: Common Stock — 1,473,271 shares (Direct); Common Stock — 1,707 shares (Indirect, Spouse's IRA)

Footnotes (1)

Shares purchased in open-market transactions. Includes 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors. Includes 1,693 shares held by the John J. Alam Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.41 to $7.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. Includes 1,707 shares held by the Sylvie Gregoire Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.44 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

Form 4 Insider Transactions: What Each Field Means →

11/17/2025 - 09:01 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALAM JOHN J

(Last)

(First)

(Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON

02116

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/13/2025		P		4,447⁽¹⁾	A	$7.51	1,471,578⁽²⁾	D
Common Stock	11/14/2025		P		1,693⁽¹⁾⁽³⁾	A	$7.55⁽³⁾	1,473,271⁽²⁾⁽³⁾	D
Common Stock	11/14/2025		P		1,707⁽¹⁾⁽⁴⁾	A	$7.57⁽⁴⁾	1,707⁽⁴⁾	I	Spouse's IRA⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares purchased in open-market transactions.

2. Includes 1,471,578 shares held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, PharmD., a member of the Issuer's Board of Directors.

3. Includes 1,693 shares held by the John J. Alam Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.41 to $7.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

4. Includes 1,707 shares held by the Sylvie Gregoire Roth IRA. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.44 to $7.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CervoMed (CRVO) report in this Form 4?

The report shows the CEO, President, director and 10% owner of CervoMed Inc. (CRVO) purchased common stock in open-market transactions on 11/13/2025 and 11/14/2025.

How many CervoMed (CRVO) shares were bought on 11/13/2025 and at what price?

On 11/13/2025, the reporting person bought 4,447 shares of CervoMed common stock at $7.51 per share in open-market transactions.

What additional CervoMed (CRVO) shares were acquired on 11/14/2025?

On 11/14/2025, the reporting person acquired 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA and 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA.

How many CervoMed (CRVO) shares does the insider hold jointly after these trades?

The filing states that 1,471,578 shares are held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, who is also a member of CervoMed’s Board of Directors.

Were the CervoMed (CRVO) shares bought in open-market transactions?

Yes. The explanations note that the shares reported were purchased in open-market transactions, with certain trades reported at weighted average prices within stated price ranges.

What price ranges applied to the weighted average CervoMed (CRVO) purchase prices?

The $7.55 weighted average price reflects purchases between $7.41 and $7.57. The $7.57 weighted average price reflects purchases between $7.44 and $7.58, all in open-market transactions.

How is indirect ownership of CervoMed (CRVO) shares reported in this Form 4?

Indirect ownership is reported through the John J. Alam Roth IRA holding 1,693 shares and the Sylvie Gregoire Roth IRA holding 1,707 shares, in addition to jointly held shares.